EP 217609

Drug Profile

EP 217609

Alternative Names: EP-217609

Latest Information Update: 02 Oct 2015

Price : $50

At a glance

  • Originator Organon
  • Developer Endotis Pharma
  • Class Antithrombins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 22 Jun 2011 Phase-II clinical trials in Thrombosis prevention in France (IV)
  • 19 Oct 2009 Phase-I clinical trials in Thrombosis in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top